HC Wainwright Issues Negative Estimate for CRBU Earnings

Caribou Biosciences, Inc. (NASDAQ:CRBU) – Equities research analysts at HC Wainwright lowered their Q3 2025 earnings per share estimates for Caribou Biosciences in a research note issued to investors on Tuesday, September 23rd. HC Wainwright analyst R. Burns now anticipates that the company will earn ($0.36) per share for the quarter, down from their prior forecast of ($0.33). The consensus estimate for Caribou Biosciences’ current full-year earnings is ($1.64) per share. HC Wainwright also issued estimates for Caribou Biosciences’ Q4 2025 earnings at ($0.37) EPS and FY2025 earnings at ($1.51) EPS.

Separately, Wall Street Zen upgraded Caribou Biosciences from a “sell” rating to a “hold” rating in a report on Sunday, August 24th. Three investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $6.67.

Caribou Biosciences Price Performance

NASDAQ CRBU opened at $1.93 on Thursday. Caribou Biosciences has a fifty-two week low of $0.66 and a fifty-two week high of $3.00. The stock’s 50-day moving average is $1.94 and its two-hundred day moving average is $1.36. The firm has a market cap of $179.72 million, a P/E ratio of -1.08 and a beta of 2.54.

Caribou Biosciences (NASDAQ:CRBU) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.05. Caribou Biosciences had a negative return on equity of 62.35% and a negative net margin of 1,800.93%.The business had revenue of $2.67 million during the quarter, compared to analyst estimates of $1.64 million.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Hudson Bay Capital Management LP bought a new position in shares of Caribou Biosciences in the second quarter valued at approximately $30,000. Tower Research Capital LLC TRC raised its stake in shares of Caribou Biosciences by 577.9% in the second quarter. Tower Research Capital LLC TRC now owns 74,053 shares of the company’s stock valued at $93,000 after acquiring an additional 63,129 shares during the last quarter. Bridgeway Capital Management LLC raised its position in Caribou Biosciences by 36.9% in the 2nd quarter. Bridgeway Capital Management LLC now owns 148,500 shares of the company’s stock worth $187,000 after purchasing an additional 40,000 shares during the last quarter. Brevan Howard Capital Management LP bought a new position in Caribou Biosciences in the 2nd quarter worth approximately $196,000. Finally, Jane Street Group LLC raised its position in Caribou Biosciences by 64.7% in the 2nd quarter. Jane Street Group LLC now owns 483,610 shares of the company’s stock worth $609,000 after purchasing an additional 189,923 shares during the last quarter. Institutional investors own 77.51% of the company’s stock.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.